Total reported value
$4.0M
Reporting period: 2026-03-31 · Number of holdings: 7
CAXTON CORP disclosed 7 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $4.0M and a quarterly turnover rate of 33.3%.
Browse other institutions with under $100M AUMBrowse other institutions starting with "C"
Add GLD
+9.5% $520.0K
Trim LXEO
0.0% -$58.4K
Add BRK-B
+2.4% -$8.4K
Trim IKT
0.0% -$10.5K
Add XFOR
0.0% $2.0K
Trim KYTX
0.0% -$14.5K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | ETF-Commodities | 81.50% | +17.00% | +9.46% | |
| 2 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 8.66% | +0.32% | +2.39% | |
| 3 | KYTX | Kyverna Therapeutics INC | Stock-Other | 4.03% | -0.09% | — | |
| 4 | LXEO | Lexeo Therapeutics INC | Stock-Other | 1.99% | -1.25% | — | |
| 5 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 1.60% | +0.15% | — | |
| 6 | IKT | Inhibikase Therapeutics INC | Stock-Other | 1.19% | -0.17% | — | |
| 7 | ALXO | Alx Oncology Holdings INC | Stock-Other | 1.04% | +1.04% | NEW |
Performance for Q3 2026
-12.2%
Performance Last 4 Quarters
-36.5%
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 7 | $4.0M | 33 | |
| 2025-12-31 | 11 | $4.3M | 100 | |
| 2025-09-30 | 12 | $22.9M | 100 | |
| 2025-06-30 | 11 | $9.9M | 0 | |
| 2025-03-31 | 12 | $5.1M | 100 | |
| 2024-12-31 | 15 | $16.6M | 0 | |
| 2024-09-30 | 12 | $24.2M | 0 | |
| 2024-06-30 | 12 | $19.7M | 0 | |
| 2024-03-31 | 11 | $17.6M | 0 | |
| 2023-12-31 | 12 | $18.5M | 0 | |
| 2023-09-30 | 9 | $26.3M | 0 | |
| 2023-06-30 | 7 | $34.7M | 0 | |
| 2023-03-31 | 15 | $39.6M | 0 | |
| 2022-12-31 | 17 | $39.1M | 0 | |
| 2022-09-30 | 17 | $53.2M | 0 | |
| 2022-06-30 | 16 | $74.4M | 0 | |
| 2022-03-31 | 37 | $80.4M | 0 | |
| 2021-12-31 | 52 | $122.3M | 0 | |
| 2021-09-30 | 55 | $123.4M | 0 | |
| 2021-06-30 | 63 | $146.0M | 26 | |
| 2021-03-31 | 69 | $153.9M | 52 | |
| 2020-12-31 | 44 | $160.4M | 57 | |
| 2020-09-30 | 17 | $106.1M | 70 | |
| 2020-06-30 | 15 | $87.3M | 52 | 16085502G85347382640U |
| 2020-03-31 | 17 | $91.5M | 50 | |
| 2019-12-31 | 40 | $103.7M | 38 | |
| 2019-09-30 | 40 | $88.7M | 50 | |
| 2019-06-30 | 31 | $88.0M | 39 | 1G8534726085503483119 |
| 2019-03-31 | 26 | $107.8M | 32 | |
| 2018-12-31 | 25 | $82.4M | 43 | |
| 2018-09-30 | 29 | $108.2M | 97 | |
| 2018-06-30 | 25 | $283.0M | 100 | |
| 2018-03-31 | 23 | $89.6M | 0 | |
| 2017-12-31 | 20 | $82.3M | 38 | 1G8534726085503483119 |
| 2017-09-30 | 16 | $98.2M | 44 | |
| 2017-06-30 | 11 | $64.1M | 60 | |
| 2017-03-31 | 10 | $35.0M | 66 | |
| 2016-12-31 | 12 | $29.3M | 86 | |
| 2016-09-30 | 14 | $22.3M | 100 | |
| 2016-06-30 | 15 | $88.6M | 94 | |
| 2016-03-31 | 18 | $72.5M | 100 | |
| 2015-12-31 | 20 | $23.8M | 100 | |
| 2015-09-30 | 19 | $74.1M | 30 | 187162T215089R374346L |
| 2015-06-30 | 19 | $94.5M | 18 | |
| 2015-03-31 | 20 | $83.8M | 19 | 187162T215089R302503Y |
| 2014-12-31 | 10 | $86.9M | 16 | |
| 2014-09-30 | 4 | $97.2M | 29 | 187162T215089R3G2554F |
| 2014-06-30 | 4 | $129.7M | 2 | 187162T215089R3G2554F |
| 2014-03-31 | 3 | $131.0M | 19 | 187162T215089R3G2554F |
| 2013-12-31 | 3 | $157.5M | 5 | |
| 2013-09-30 | 2 | $149.3M | 23 | 187162T2HALLUSD |
| 2013-06-30 | 2 | $118.2M | 40 | 187162T2HALLUSD |
Caxton CORP's most significant position changes for 2026-03-31: Sold out: Spyre Therapeutics INC (SYRE); Sold out: Mind Medicine Mindmed INC (BRD1EUR); Sold out: Compass Therapeutics INC (CMPX); New buy: Alx Oncology Holdings INC (ALXO); Sold out: Sab Biotherapeutics INC (SABS).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | +17% | +9.46% | Add |
| 2 | BRK-B | Berkshire Hathaway Inc-cl B | +0.3% | +2.39% | Add |
| 3 | XFOR | X4 Pharmaceuticals INC | +0.2% | — | Unchanged |
| 4 | KYTX | Kyverna Therapeutics INC | -0.1% | — | Unchanged |
| 5 | IKT | Inhibikase Therapeutics INC | -0.2% | — | Unchanged |
| 6 | LXEO | Lexeo Therapeutics INC | -1.3% | — | Unchanged |
| 7 | SYRE | Spyre Therapeutics INC | — | EXIT | Sold out |
| 8 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 9 | CMPX | Compass Therapeutics INC | — | EXIT | Sold out |
| 10 | ALXO | Alx Oncology Holdings INC | — | NEW | New buy |
| 11 | SABS | Sab Biotherapeutics INC | — | EXIT | Sold out |
| 12 | CNTX | Context Therapeutics INC | — | EXIT | Sold out |
Institutions with a similar AUM
CIK 0001674114
Total reported value
$4.0M
1 stks
2021-12-31
Stale — no recent filing
AUM within 0.4% of this institution
CIK 0001935942
Total reported value
$4.1M
1 stks
2022-06-30
Stale — no recent filing
AUM within 1.2% of this institution
CIK 0001298477
Total reported value
$4.1M
2 stks
2014-09-30
Stale — no recent filing
AUM within 1.2% of this institution
Institutions with overlapping top holdings
CIK 0001509873
Total reported value
$166.7M
65 stks
2026-03-31
2 of the top 5 holdings overlap, including Spdr Gold Shares
CIK 0001536550
Total reported value
$248.3M
236 stks
2016-09-30
Stale — no recent filing
2 of the top 5 holdings overlap, including Spdr Gold Shares
CIK 0001922962
Total reported value
$173.9M
87 stks
2025-06-30
Stale — no recent filing
2 of the top 5 holdings overlap, including Berkshire Hathaway Inc-cl B